Household & Personal Products
Compare Stocks
5 / 10Stock Comparison
EWCZ vs FAT vs SKIN vs LFST vs XPOF
Revenue, margins, valuation, and 5-year total return — side by side.
Restaurants
Household & Personal Products
Medical - Care Facilities
Leisure
EWCZ vs FAT vs SKIN vs LFST vs XPOF — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Household & Personal Products | Restaurants | Household & Personal Products | Medical - Care Facilities | Leisure |
| Market Cap | $273M | $3M | $118M | $3.43B | $244M |
| Revenue (TTM) | $211M | $574M | $296M | $1.49B | $299M |
| Net Income (TTM) | $11M | $-226M | $-6M | $23M | $-34M |
| Gross Margin | 69.4% | 27.4% | 64.9% | 21.7% | 83.2% |
| Operating Margin | 24.4% | -14.1% | -3.6% | 3.0% | 7.8% |
| Forward P/E | 8.5x | — | — | 121.1x | 10.9x |
| Total Debt | $381M | $1.47B | $379M | $194M | $525M |
| Cash & Equiv. | $50M | $23M | $233M | $249M | $46M |
EWCZ vs FAT vs SKIN vs LFST vs XPOF — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Aug 21 | May 26 | Return |
|---|---|---|---|
| European Wax Center… (EWCZ) | 100 | 23.9 | -76.1% |
| FAT Brands Inc. (FAT) | 100 | 3.0 | -97.0% |
| The Beauty Health C… (SKIN) | 100 | 3.5 | -96.5% |
| LifeStance Health G… (LFST) | 100 | 59.6 | -40.4% |
| Xponential Fitness,… (XPOF) | 100 | 60.6 | -39.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: EWCZ vs FAT vs SKIN vs LFST vs XPOF
Each card shows where this stock fits in a portfolio — not just who wins on paper.
EWCZ carries the broadest edge in this set and is the clearest fit for defensive.
- Beta 1.46, yield 0.3%, current ratio 2.43x
- Lower P/E (8.5x vs 10.9x)
- 5.3% margin vs FAT's -39.3%
- +68.7% vs FAT's -94.2%
FAT is the #2 pick in this set and the best alternative if income & stability and long-term compounding is your priority.
- Dividend streak 0 yrs, beta 1.56, yield 100.0%
- -14.2% 10Y total return vs XPOF's -46.6%
- 23.4% revenue growth vs SKIN's -10.0%
- 100.0% yield, vs EWCZ's 0.3%, (2 stocks pay no dividend)
SKIN lags the leaders in this set but could rank higher in a more targeted comparison.
LFST ranks third and is worth considering specifically for growth exposure and sleep-well-at-night.
- Rev growth 13.9%, EPS growth 113.3%, 3Y rev CAGR 18.3%
- Lower volatility, beta 1.20, Low D/E 12.8%, current ratio 1.65x
- Beta 1.20 vs SKIN's 2.00, lower leverage
Among these 5 stocks, XPOF doesn't own a clear edge in any measured category.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 23.4% revenue growth vs SKIN's -10.0% | |
| Value | Lower P/E (8.5x vs 10.9x) | |
| Quality / Margins | 5.3% margin vs FAT's -39.3% | |
| Stability / Safety | Beta 1.20 vs SKIN's 2.00, lower leverage | |
| Dividends | 100.0% yield, vs EWCZ's 0.3%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +68.7% vs FAT's -94.2% | |
| Efficiency (ROA) | 1.6% ROA vs FAT's -18.0%, ROIC 8.3% vs -3.8% |
EWCZ vs FAT vs SKIN vs LFST vs XPOF — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
EWCZ vs FAT vs SKIN vs LFST vs XPOF — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
LFST leads in 2 of 6 categories
FAT leads 2 • EWCZ leads 1 • SKIN leads 1 • XPOF leads 0
Explore the data ↓Income & Cash Flow (Last 12 Months)
EWCZ leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
LFST is the larger business by revenue, generating $1.5B annually — 7.1x EWCZ's $211M. EWCZ is the more profitable business, keeping 5.3% of every revenue dollar as net income compared to FAT's -39.3%. On growth, LFST holds the edge at +21.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $211M | $574M | $296M | $1.5B | $299M |
| EBITDAEarnings before interest/tax | $72M | -$44M | $9M | $100M | $35M |
| Net IncomeAfter-tax profit | $11M | -$226M | -$6M | $23M | -$34M |
| Free Cash FlowCash after capex | $59M | -$75M | $29M | $179M | -$3M |
| Gross MarginGross profit ÷ Revenue | +69.4% | +27.4% | +64.9% | +21.7% | +83.2% |
| Operating MarginEBIT ÷ Revenue | +24.4% | -14.1% | -3.6% | +3.0% | +7.8% |
| Net MarginNet income ÷ Revenue | +5.3% | -39.3% | -2.0% | +1.6% | -11.3% |
| FCF MarginFCF ÷ Revenue | +28.1% | -13.1% | +9.8% | +12.0% | -1.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | -2.2% | -2.3% | -6.7% | +21.2% | -21.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +182.1% | -23.7% | +38.0% | — | +79.1% |
Valuation Metrics
SKIN leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
At 26.5x trailing earnings, EWCZ trades at a 94% valuation discount to LFST's 442.5x P/E. On an enterprise value basis, XPOF's 7.9x EV/EBITDA is more attractive than SKIN's 7331.2x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $273M | $3M | $118M | $3.4B | $244M |
| Enterprise ValueMkt cap + debt − cash | $604M | $1.5B | $264M | $3.4B | $723M |
| Trailing P/EPrice ÷ TTM EPS | 26.45x | -0.01x | -5.69x | 442.50x | -4.45x |
| Forward P/EPrice ÷ next-FY EPS est. | 8.47x | — | — | 121.07x | 10.90x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 8.88x | — | 7331.15x | 41.98x | 7.89x |
| Price / SalesMarket cap ÷ Revenue | 1.26x | 0.00x | 0.39x | 2.41x | 0.78x |
| Price / BookPrice ÷ Book value/share | 2.98x | — | 2.02x | 2.28x | — |
| Price / FCFMarket cap ÷ FCF | 4.87x | — | 3.17x | 31.20x | 9.86x |
Profitability & Efficiency
LFST leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
EWCZ delivers a 10.7% return on equity — every $100 of shareholder capital generates $11 in annual profit, vs $-9 for SKIN. LFST carries lower financial leverage with a 0.13x debt-to-equity ratio, signaling a more conservative balance sheet compared to SKIN's 6.20x. On the Piotroski fundamental quality scale (0–9), EWCZ scores 7/9 vs FAT's 2/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +10.7% | — | -9.4% | +1.6% | — |
| ROA (TTM)Return on assets | +1.6% | -18.0% | -1.2% | +1.1% | -9.5% |
| ROICReturn on invested capital | +8.3% | -3.8% | -6.8% | +1.2% | +75.0% |
| ROCEReturn on capital employed | +7.0% | -5.0% | -4.5% | +1.3% | +30.3% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 2 | 7 | 7 | 5 |
| Debt / EquityFinancial leverage | 4.16x | — | 6.20x | 0.13x | — |
| Net DebtTotal debt minus cash | $331M | $1.5B | $146M | -$55M | $479M |
| Cash & Equiv.Liquid assets | $50M | $23M | $233M | $249M | $46M |
| Total DebtShort + long-term debt | $381M | $1.5B | $379M | $194M | $525M |
| Interest CoverageEBIT ÷ Interest expense | 1.78x | -0.54x | 0.81x | 3.30x | -0.24x |
Total Returns (Dividends Reinvested)
FAT leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in FAT five years ago would be worth $9,149 today (with dividends reinvested), compared to $707 for SKIN. Over the past 12 months, EWCZ leads with a +68.7% total return vs FAT's -94.2%. The 3-year compound annual growth rate (CAGR) favors FAT at 6.8% vs SKIN's -56.4% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +69.2% | -52.3% | -35.0% | +27.2% | -18.5% |
| 1-Year ReturnPast 12 months | +68.7% | -94.2% | -35.9% | +60.6% | -22.6% |
| 3-Year ReturnCumulative with dividends | -67.0% | +21.9% | -91.7% | +4.1% | -77.4% |
| 5-Year ReturnCumulative with dividends | -57.4% | -8.5% | -92.9% | -59.6% | -46.6% |
| 10-Year ReturnCumulative with dividends | -57.4% | -14.2% | -91.6% | -59.6% | -46.6% |
| CAGR (3Y)Annualised 3-year return | -30.9% | +6.8% | -56.4% | +1.4% | -39.1% |
Risk & Volatility
LFST leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
LFST is the less volatile stock with a 1.20 beta — it tends to amplify market swings less than SKIN's 2.00 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LFST currently trades 99.6% from its 52-week high vs FAT's 4.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.46x | 1.56x | 2.00x | 1.20x | 1.94x |
| 52-Week HighHighest price in past year | $6.52 | $3.45 | $2.69 | $8.89 | $11.14 |
| 52-Week LowLowest price in past year | $3.22 | $0.06 | $0.76 | $3.74 | $3.83 |
| % of 52W HighCurrent price vs 52-week peak | +89.3% | +4.7% | +33.8% | +99.6% | +58.7% |
| RSI (14)Momentum oscillator 0–100 | 56.3 | 32.2 | 52.1 | 60.4 | 48.4 |
| Avg Volume (50D)Average daily shares traded | 619K | 85K | 760K | 2.9M | 626K |
Analyst Outlook
FAT leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: EWCZ as "Hold", SKIN as "Hold", LFST as "Buy", XPOF as "Buy". Consensus price targets imply 42.9% upside for SKIN (target: $1) vs -0.3% for EWCZ (target: $6). For income investors, FAT offers the higher dividend yield at 100.00% vs EWCZ's 0.29%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | — | Hold | Buy | Buy |
| Price TargetConsensus 12-month target | $5.80 | — | $1.30 | $9.30 | $8.00 |
| # AnalystsCovering analysts | 8 | — | 13 | 11 | 14 |
| Dividend YieldAnnual dividend ÷ price | +0.3% | +100.0% | — | — | +2.5% |
| Dividend StreakConsecutive years of raises | 0 | 0 | — | — | 0 |
| Dividend / ShareAnnual DPS | $0.02 | $0.56 | — | — | $0.16 |
| Buyback YieldShare repurchases ÷ mkt cap | +14.7% | 0.0% | 0.0% | 0.0% | 0.0% |
LFST leads in 2 of 6 categories (Profitability & Efficiency, Risk & Volatility). FAT leads in 2 (Total Returns, Analyst Outlook).
EWCZ vs FAT vs SKIN vs LFST vs XPOF: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is EWCZ or FAT or SKIN or LFST or XPOF a better buy right now?
For growth investors, FAT Brands Inc.
(FAT) is the stronger pick with 23. 4% revenue growth year-over-year, versus -10. 0% for The Beauty Health Company (SKIN). European Wax Center, Inc. (EWCZ) offers the better valuation at 26. 5x trailing P/E (8. 5x forward), making it the more compelling value choice. Analysts rate LifeStance Health Group, Inc. (LFST) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — EWCZ or FAT or SKIN or LFST or XPOF?
On trailing P/E, European Wax Center, Inc.
(EWCZ) is the cheapest at 26. 5x versus LifeStance Health Group, Inc. at 442. 5x. On forward P/E, European Wax Center, Inc. is actually cheaper at 8. 5x.
03Which is the better long-term investment — EWCZ or FAT or SKIN or LFST or XPOF?
Over the past 5 years, FAT Brands Inc.
(FAT) delivered a total return of -8. 5%, compared to -92. 9% for The Beauty Health Company (SKIN). Over 10 years, the gap is even starker: FAT returned -14. 2% versus SKIN's -91. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — EWCZ or FAT or SKIN or LFST or XPOF?
By beta (market sensitivity over 5 years), LifeStance Health Group, Inc.
(LFST) is the lower-risk stock at 1. 20β versus The Beauty Health Company's 2. 00β — meaning SKIN is approximately 67% more volatile than LFST relative to the S&P 500. On balance sheet safety, LifeStance Health Group, Inc. (LFST) carries a lower debt/equity ratio of 13% versus 6% for The Beauty Health Company — giving it more financial flexibility in a downturn.
05Which is growing faster — EWCZ or FAT or SKIN or LFST or XPOF?
By revenue growth (latest reported year), FAT Brands Inc.
(FAT) is pulling ahead at 23. 4% versus -10. 0% for The Beauty Health Company (SKIN). On earnings-per-share growth, the picture is similar: LifeStance Health Group, Inc. grew EPS 113. 3% year-over-year, compared to -98. 3% for FAT Brands Inc.. Over a 3-year CAGR, FAT leads at 70. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — EWCZ or FAT or SKIN or LFST or XPOF?
European Wax Center, Inc.
(EWCZ) is the more profitable company, earning 4. 8% net margin versus -32. 0% for FAT Brands Inc. — meaning it keeps 4. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: XPOF leads at 25. 3% versus -8. 8% for FAT. At the gross margin level — before operating expenses — XPOF leads at 75. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is EWCZ or FAT or SKIN or LFST or XPOF more undervalued right now?
On forward earnings alone, European Wax Center, Inc.
(EWCZ) trades at 8. 5x forward P/E versus 121. 1x for LifeStance Health Group, Inc. — 112. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SKIN: 42. 9% to $1. 30.
08Which pays a better dividend — EWCZ or FAT or SKIN or LFST or XPOF?
In this comparison, FAT (100.
0% yield), XPOF (2. 5% yield), EWCZ (0. 3% yield) pay a dividend. SKIN, LFST do not pay a meaningful dividend and should not be held primarily for income.
09Is EWCZ or FAT or SKIN or LFST or XPOF better for a retirement portfolio?
For long-horizon retirement investors, FAT Brands Inc.
(FAT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (100. 0% yield). The Beauty Health Company (SKIN) carries a higher beta of 2. 00 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (FAT: -14. 2%, SKIN: -91. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between EWCZ and FAT and SKIN and LFST and XPOF?
These companies operate in different sectors (EWCZ (Consumer Defensive) and FAT (Consumer Cyclical) and SKIN (Consumer Defensive) and LFST (Healthcare) and XPOF (Consumer Cyclical)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: EWCZ is a small-cap quality compounder stock; FAT is a small-cap high-growth stock; SKIN is a small-cap quality compounder stock; LFST is a small-cap quality compounder stock; XPOF is a small-cap quality compounder stock. FAT, XPOF pay a dividend while EWCZ, SKIN, LFST do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.